Hyderabad:Aurobindo Pharmahas announced thatCuraTeQ Biologics B.V., a wholly owned step-down subsidiary of the Company, has incorporated a new wholly owned subsidiary in Malta by the name of CuraTeQ Biologics (Malta) Limited. The incorporation is aimed at expanding the company’s pharmaceutical products business in Malta. According to the company’s disclosure to the BSE, CuraTeQ Biologics (Malta) Limited will operate in the pharmaceutical sector. Earlier this month, Helix Healthcare B.V., a wholly owned subsidiary of the Company, also incorporated a new wholly owned subsidiary in Malaysia by the name of Aurobindo Pharma (Malaysia) SDN. BHD. Read also:Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia In June, the Company further extended its global presence by incorporating a wholly owned subsidiary in the United States through Aurobindo Pharma USA Inc. Read also:Aurobindo Pharma arm incorporates new subsidiary in US Additionally, in May 2025, Curateq Biologics Private Limited, another wholly owned subsidiary of Aurobindo, incorporated a new wholly owned subsidiary in the Netherlands by the name of CuraTeQ Biologics B.V. Further strengthening its domestic capabilities, in October 2024, Lyfius Pharma, a wholly owned step-down subsidiary of Aurobindo Pharma, inaugurated its state-of-the-art PenG manufacturing facility, at Kakinada, Andhra Pradesh. Headquartered in Hyderabad, India, Aurobindo Pharma Ltd. is a global pharmaceutical company with operations spanning active pharmaceutical ingredients (APIs), generics, and biosimilars. CuraTeQ Biologics is its wholly owned subsidiary focused on biosimilars for oncology and other therapeutic areas, enhancing Aurobindo’s footprint in biologics markets in Europe and beyond.